Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > ebr > summer 2004 > the ipo window reopens - are you ready?

PUBLICATIONS

European BioPharmaceutical Review The IPO Window Reopens - Are you Ready?
Whisper it quietly, but the IPO window may just have reopened for European biotechs. Ark Therapeutics' flotation in March this year has led to a spate of similar launches of biotech stocks onto the public markets after a dearth of opportunities in recent years. The position undoubtedly remains volatile. Only the best companies will be allowed to list and, as ever, due diligence will be key. This article looks at the importance of legal due diligence in the context of an impending IPO and asks are you ready to take advantage of the IPO window - which may yet prove shortlived.
Read full article >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

By Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors

Patrick Martin is a Partner and Corporate and Commercial Lawyer at McGrigors, with a particular emphasis on the health care and life sciences fields, acting for both investors and companies. He has advised on numerous technology start-ups and spin-outs, fundraisings and private placements for biotech companies and IPOs. Patrick has specialised in private equity work for over 14 years.

Martin Finnegan is a senior Corporate Solicitor at McGrigors and part of the firm's public equity group. Martin has advised on numerous IPOs and public equity issues acting for sponsors and companies, and is a member of the legal committee of the Quoted Companies Alliance (QCA).